The economics of treatment in early rheumatoid arthritis
Authors:
- Nick BansbackNBNick Bansback
- Carlo A. MarraCMCarlo A. Marra
- Axel FinckhAFAxel Finckh
- Aslam AnisAAAslam Anis
- 1 February 2009
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 23 (1) , 83-92
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Cost-Effectiveness of Sequential Therapy with Tumor Necrosis Factor Antagonists in Early Rheumatoid ArthritisThe Journal of Rheumatology, 2009
- Long‐term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta‐analysisArthritis Care & Research, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- The Indirect Costs of Arthritis Resulting From Unemployment, Reduced Performance, and Occupational Changes While at WorkMedical Care, 2006
- Measuring the effects of work loss on productivity with team productionHealth Economics, 2005
- Willingness to Pay for a QALYPharmacoEconomics, 2005
- An Overview of Economic Evaluations for Drugs Used in Rheumatoid ArthritisDrugs, 2005
- Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmesHealth Economics, 2004
- COBRA combination therapy in patients with early rheumatoid arthritis: Long‐term structural benefits of a brief interventionArthritis & Rheumatism, 2002
- Carrier Screening for Cystic FibrosisMedical Decision Making, 1998